论文部分内容阅读
目的 研究来氟米特对类风湿关节炎的疗效及安全性 ,并与甲氨蝶呤 (MTX)进行对照。方法 60例活动性RA病人分别用来氟米特 ( 2 0mg/周 )及MTX( 15mg/周 )治疗 ,疗程为 2 4周 ,对两药在 12、2 4周时的疗效及观察指标进行评估。结果 来氟米特在 12、2 4周时的有效率分别为80 0 % ,83 3 % ,MTX为 70 0 % ,显示来氟米特对RA的疗效与MTX相近。来氟米特能显著改善临床实验观察指标 ,来氟米特的耐受性较MTX为好 ,其主要不良反应为消化道副作用。结论 来氟米特为一新的有效的治疗RA的药物 ,且较安全。
Objective To study the efficacy and safety of leflunomide against rheumatoid arthritis and to compare with methotrexate (MTX). Methods Sixty patients with active RA were treated with leflunomide (20 mg / week) and MTX (15 mg / week) respectively for 24 weeks. The efficacy and observation of two drugs at 12 and 24 weeks Evaluation. Results The effective rates of leflunomide at 12 and 24 weeks were 80 0% and 83 3%, respectively. The MTX was 70%. The efficacy of leflunomide on RA was similar to that on MTX. Leflunomide can significantly improve the clinical experimental observation indicators, leflunomide tolerance than MTX is better, the main side effects of gastrointestinal side effects. Conclusion Leflunomide is a new and effective drug for the treatment of RA, and is safer.